Suppr超能文献

阵发性睡眠性血红蛋白尿症患者分选的 CD34+CD59+ 细胞的体外扩增和长期造血重建能力。

Ex vivo expansion and long-term hematopoietic reconstitution ability of sorted CD34+CD59+ cells from patients with paroxysmal nocturnal hemoglobinuria.

机构信息

Department of Pediatrics, Peking Union Medical College Hospital, Chinese Academe of Medical Science, Beijing, China.

出版信息

Int J Hematol. 2010 Jul;92(1):58-67. doi: 10.1007/s12185-010-0628-3. Epub 2010 Jun 25.

Abstract

Autologous bone marrow transplantation (ABMT) for paroxysmal nocturnal hemoglobinuria (PNH) remains difficult so far. To expand residual normal CD34(+)CD59(+) cells isolated from patients with PNH and observe the long-term hematopoietic reconstruction ability of the expanded cells both ex vivo and in vivo, CD34(+)CD59(+) cells from 13 PNH patients and CD34(+) cells from 11 normal controls were separated from bone marrow mononuclear cells first by immunomagnetic microbeads and then by flow cytometry autoclone sorting. The cells were then cultivated under different conditions. The long-term hematopoietic supporting ability of expanded CD34(+)CD59(+) cells was evaluated by long-term culture in semi-solid medium in vitro and long-term engraftment in irradiated severe combined immunodeficiency (SCID) mice in vivo. The best combination of hematopoietic growth factors for ex vivo expansion was SCF + IL-3 + IL-6 + FL + Tpo + Epo. The most suitable time for harvest was on day 7. CD34(+)CD59(+) PNH cells retained strong colony-forming capacity even after expansion. The survival rate, complete blood cell count recovery on day 90, and human CD45 expression in different organs were similar between the irradiated SCID mice transplanted with expanded CD34(+)CD59(+) PNH cells and those with normal CD34(+) cells (P > 0.05) both in primary and secondary transplantation. These data provided a new potential way of managing PNH with ABMT.

摘要

自体骨髓移植(ABMT)治疗阵发性睡眠性血红蛋白尿症(PNH)至今仍然困难。为了扩增从 PNH 患者中分离出的残留正常 CD34+CD59+细胞,并观察扩增细胞在体外和体内的长期造血重建能力,首先通过免疫磁珠和流式细胞仪自动克隆分选从 13 例 PNH 患者和 11 例正常对照的骨髓单个核细胞中分离出 CD34+CD59+细胞和 CD34+细胞。然后在不同条件下培养这些细胞。通过体外半固体培养基长期培养和体内照射重度联合免疫缺陷(SCID)小鼠长期植入来评估扩增 CD34+CD59+细胞的长期造血支持能力。体外扩增的最佳造血生长因子组合为 SCF+IL-3+IL-6+FL+Tpo+Epo。最适宜的收获时间为第 7 天。即使在扩增后,CD34+CD59+PNH 细胞仍保持较强的集落形成能力。在原发性和继发性移植中,接受扩增的 CD34+CD59+PNH 细胞和正常 CD34+细胞移植的照射 SCID 小鼠的存活率、第 90 天的全血细胞计数恢复以及不同器官中的人 CD45 表达均相似(P>0.05)。这些数据为 PNH 的 ABMT 提供了一种新的潜在方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验